Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS

Bioanalysis

Volumn 3, Issue 2, 2011, Pages 157-165

  Lindegardh, Niklas ^a,b   Hanpithakpong, Warunee ^a   Kamanikom, Benjamas ^a   Farrar, Jeremy ^b,c   Hien, Tran Tinh ^c   Singhasivanon, Pratap ^a   White, Nicholas J ^a,b   Day, Nicholas P J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; ISOTOPE LABELING; LIMIT OF QUANTITATION; MASS SPECTROMETRY; PLASMA VOLUME; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SOLID PHASE EXTRACTION; VALIDATION STUDY;

ANTIVIRAL AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; INFLUENZA, HUMAN; PLASMA; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY; ZANAMIVIR;

EID: 79951925101     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.189     Document Type: Article

References (20)

1. Taubenberger JK, Morens DM. Infuenza: the once and future pandemic. Public Health Rep. 125(Suppl. 3), 16-26 (2010).
2. Taubenberger JK, Morens DM, Fauci AS. The next infuenza pandemic: can it be predicted? JAMA 297(18), 2025-2027 (2007). (Pubitemid 46740355)
3. Normile D. Avian infuenza. WHO proposes plan to stop pandemic in its tracks. Science 311(5759), 315-316 (2006). (Pubitemid 43132624)
4. No authors listed. How to win trust over fu. Nature 461(7265), 698 (2009).
5. Schwarzinger M, Flicoteaux R, Cortarenoda S, Obadia Y, Moatti JP. Low acceptability of a/h1n1 pandemic vaccination in French adult population: did public health policy fuel public dissonance? PLoS ONE 5(4), e10199 (2010).
6. Stone R. Swine fu outbreak. China frst to vaccinate against novel H1N1 virus. Science 325(5947), 1482-1483 (2009).
7. Patel A, Gorman SE. Stockpiling antiviral drugs for the next infuenza pandemic. Clin. Pharmacol. Ther. 86(3), 241-243 (2009).
8. Hayden F, Klimov A, Tashiro M et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in infuenza a/H5N1 viruses. Antivir. Ther. 10(8), 873-877 (2005). (Pubitemid 43076338)
9. Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA. Drugs in development for infuenza. Drugs 70(11), 1349-1362 (2010).
10. Hayden F. Developing new antiviral agents for infuenza treatment: what does the future hold? Clin. Infect. Dis. 48(Suppl. 1), S3-S13 (2009).
11. Stubbs RJ, Harker AJ. Automated high-performance liquid chromatographic method for the determination of a neuraminidase inhibitor (GG167) in human serum by precolumn fuorescence derivatisation using benzoin. J. Chromatogr. B Biomed. Appl. 670(2), 279-285 (1995).
12. Morris DM, Hussey BK, Geurin SL, Selinger KA. Determination of the novel sialic acid analog GG167 (GR121167x) in human urine by LC: direct injection with column switching. J. Pharm. Biomed. Anal. 14(1-2), 191-201 (1995). (Pubitemid 26146025)
13. Allen GD, Brookes ST, Barrow A, Dunn JA, Grosse CM. Liquid chromatographic-tandem mass spectrometric method for the determination of the neuraminidase inhibitor zanamivir (GG167) in human serum. J. Chromatogr. B Biomed. Sci. Appl. 732(2), 383-393 (1999). (Pubitemid 29460855)
14. Baughman TM, Wright WL, Hutton KA. Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852(1-2), 505-511 (2007). (Pubitemid 46830143)
15. U.S. Department of Health and Human Services, Food and Drug administration, Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Centre (CVM). Guidance for industry: bioanalytical method validation. (2001).
16. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007). (Pubitemid 47389236)
17. Singtoroj T, Tarning J, Annerberg A et al. A new approach to evaluate regression models during validation of bioanalytical assays. J. Pharm. Biomed. Anal. 41(1), 219-227 (2006).
18. Chanteux H, Paternotte I, Mingeot-Leclercq MP, Brasseur R, Sonveaux E, Tulkens PM. Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethyl-ampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. Pharm. Res. 20(4), 624-631 (2003). (Pubitemid 36438907)
19. Lindegardh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon P, White NJ, Day NP. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 859(1), 74-83 (2007). (Pubitemid 47626090)
20. Lindegardh N, Hanpithakpong W, Phakdeeraj A et al. Development and validation of a high-throughput zwitterionic hydrophilic interaction LC solid-phase extraction-LC-tandem mass spectrometry method for determination of the anti-infuenza drug peramivir in plasma. J. Chromatogr. A 1215(1-2) 145-151 (2008).